EU Safety Gate (RAPEX) · Estonia · 2023-12-01 · Serious risk
🌐Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Reported risk: Kõrvarõngad sisaldavad liiga suures kontsentratsioonis pliid (mõõdetud väärtus üle 45% massist). Plii on kahjulik inimese tervisele, koguneb organismi ja võib mõjutada rinnaga toidetavaid või sündimata lapsi. Toode eraldab liiga palju niklit (mõõdetud väärtus kuni 3,87 μg/cm²/nädalas). Nikkel on tugev sensibilisaator ja võib põhjustada allergilisi reaktsioone, kui see esineb esemetes, mis puutuvad otseselt ja pikaajaliselt kokku nahaga. Toode ei vasta REACH-määruse nõuetele.
Action taken by the authority
Type of economic operator taking notified measure
Retailer
Category of measure
Recall of the product from end users
Date of entry into force
10/11/2023
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.
Risk Description (original English): The earrings have an excessive concentration of lead (measured value more than 45% by weight). Lead is harmful to human health, accumulates in the body and may affect breast-fed or unborn children. The product releases an excessive amount of nickel (measured value up to 3.87 μg/cm²/week). Nickel is a strong sensitiser and can cause allergic reactions if present in articles that come into direct and prolonged contact with the skin.
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.